Eton Pharmaceuticals, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Eton Pharmaceuticals, Inc. (ETON) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $45.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $36.00K, a 176.92% increase year-over-year.
- Eton Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $9.00K, a 47.06% decline year-over-year.
- Eton Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $9.00K, a 47.06% decline year-over-year.
- Eton Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $5.00K, a 70.59% decline year-over-year.
- Eton Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $44.00K, a 37.14% decline from fiscal 2024.
- Eton Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $70.00K, a 4.48% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $67.00K, a 8.06% increase from fiscal 2022.
- Eton Pharmaceuticals, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $62.00K, a 29.55% decline from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $45.00K 10-Q · filed 2026-08-13 | $54.00K derived: sum of 3 quarters · filed 2026-08-13 | $59.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $9.00K 10-Q · filed 2026-05-14 | $18.00K derived: sum of 2 quarters · filed 2026-05-14 | $23.00K derived: sum of 3 quarters · filed 2026-05-14 | $36.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $14.00K derived: sum of 2 quarters · filed 2026-03-19 | $27.00K derived: sum of 3 quarters · filed 2026-08-13 | $44.00K 10-K · filed 2026-03-19 | ||
| 2025-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $18.00K derived: sum of 2 quarters · filed 2026-08-13 | $35.00K 10-Q · filed 2025-11-06 | $52.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $30.00K 10-Q · filed 2026-08-13 | $47.00K derived: sum of 3 quarters · filed 2026-08-13 | $64.00K derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $17.00K 10-Q · filed 2026-05-14 | $34.00K derived: sum of 2 quarters · filed 2026-05-14 | $51.00K derived: sum of 3 quarters · filed 2026-05-14 | $69.00K derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $70.00K 10-K · filed 2025-03-18 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $34.00K derived: sum of 2 quarters · filed 2026-03-19 | $52.00K derived: sum of 3 quarters · filed 2026-03-19 | $70.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $35.00K derived: sum of 2 quarters · filed 2025-11-06 | $53.00K 10-Q · filed 2025-11-06 | $70.00K derived: sum of 4 quarters · filed 2026-03-19 | ||
| 2024-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $36.00K 10-Q · filed 2025-08-07 | $53.00K derived: sum of 3 quarters · filed 2026-03-19 | $64.00K derived: sum of 4 quarters · filed 2026-03-19 | ||
| 2024-03-31 | $18.00K 10-Q · filed 2025-05-13 | $35.00K derived: sum of 2 quarters · filed 2026-03-19 | $46.00K derived: sum of 3 quarters · filed 2026-03-19 | $66.00K derived: sum of 4 quarters · filed 2026-03-19 | ||
| 2023-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $28.00K derived: sum of 2 quarters · filed 2026-03-19 | $48.00K derived: sum of 3 quarters · filed 2026-03-19 | $67.00K 10-K · filed 2026-03-19 | ||
| 2023-09-30 | $11.00K 10-Q · filed 2023-11-09 | $31.00K derived: sum of 2 quarters · filed 2023-11-09 | $50.00K 10-Q · filed 2024-11-12 | $50.00K derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-06-30 | $20.00K 10-Q · filed 2023-08-10 | $39.00K 10-Q · filed 2024-08-08 | $39.00K derived: sum of 3 quarters · filed 2025-03-18 | $60.00K derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-03-31 | $19.00K 10-Q · filed 2024-05-09 | $19.00K derived: sum of 2 quarters · filed 2025-03-18 | $40.00K derived: sum of 3 quarters · filed 2025-03-18 | $61.00K derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $21.00K derived: sum of 2 quarters · filed 2025-03-18 | $42.00K derived: sum of 3 quarters · filed 2025-03-18 | $62.00K 10-K · filed 2025-03-18 | $82.00K 10-K · filed 2023-03-16 | |
| 2022-09-30 | $21.00K 10-Q · filed 2023-11-09 | $42.00K derived: sum of 2 quarters · filed 2023-11-09 | $62.00K 10-Q · filed 2023-11-09 | $81.00K derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | $21.00K 10-Q · filed 2023-08-10 | $41.00K 10-Q · filed 2023-08-10 | $60.00K derived: sum of 3 quarters · filed 2024-03-14 | $80.00K derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | $20.00K 10-Q · filed 2023-05-11 | $39.00K derived: sum of 2 quarters · filed 2024-03-14 | $59.00K derived: sum of 3 quarters · filed 2024-03-14 | $79.00K derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2021-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $39.00K derived: sum of 2 quarters · filed 2024-03-14 | $59.00K derived: sum of 3 quarters · filed 2024-03-14 | $88.00K 10-K · filed 2024-03-14 | ||
| 2021-09-30 | $20.00K 10-Q · filed 2022-11-10 | $40.00K derived: sum of 2 quarters · filed 2022-11-10 | $69.00K 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $20.00K 10-Q · filed 2022-08-11 | $49.00K 10-Q · filed 2022-08-11 | ||||
| 2021-03-31 | $29.00K 10-Q · filed 2022-05-12 | |||||
| 2020-12-31 | $129.00K 10-K · filed 2023-03-16 | |||||
| 2019-12-31 | $121.00K 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |